Inhaled mannitol for cystic fibrosis

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Clinical Trials

Background:

• Cystic Fibrosis (CF) patients often require airway secretion clearance.
• Mannitol, a dry powder inhalant, offers a potentially convenient alternative to nebulized mucolytics.
• Previous reviews have assessed mannitol's efficacy and safety in CF management.

Purpose of the Study:

• To evaluate the tolerability of inhaled dry powder mannitol in CF patients.
• To assess mannitol's impact on quality of life and respiratory function in CF.
• To identify adverse events associated with mannitol treatment.

Main Methods:

• Systematic review of randomized controlled trials comparing mannitol to placebo, active comparators, or no treatment.
• Searched Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register.
• Independent assessment of study inclusion, data extraction, and risk of bias; GRADE for evidence quality.

Main Results:

• Moderate-quality evidence shows mannitol improved lung function (FEV1) over six months compared to control.
• Low to very low-quality evidence indicated no consistent differences in quality of life.
• Adverse events like cough and bronchospasm were reported but not significantly different between groups; comparisons with dornase alfa showed no significant differences in lung function or quality of life.

Conclusions:

• Mannitol demonstrates moderate-quality evidence for improving lung function in CF patients over six months.
• Low-quality evidence suggests no significant impact on quality of life.
• Further research is needed to determine optimal use, long-term benefits, and comparative efficacy against established mucolytics.